Recent Updates
Recently added Catalysts

BG-T0050

Phase 1

Diffuse Large B-Cell Lymphoma | Small molecule | Other |BeOne Medicines Ltd.|Trials Updated: Oct 19, 2026

BG-T0050 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

BG-T0050 clinical trials

BG-T0050 · 1 trial · 2 indications

Phase 1 1
NCT07881211A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell MalignanciesDiffuse Large B-Cell Lymphoma
NOT YET_RECRUITING70 Analytics
PHASE1NOT YET_RECRUITING
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
Diffuse Large B-Cell Lymphoma
NCT0788121170
Unlock trial analytics

Study Endpoints

Primary Endpoints

Part 1a Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Approximately 1 Month
Part 1a and Part 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
From first dose until 30 days after the last dose; approximately 13 months

Secondary Endpoints

Overall Response Rate (ORR) Assessed by the Investigator
Approximately 24 months
Complete Response Rate (CRR)
Approximately 24 months
Duration of Response (DOR)
Approximately 24 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1a Dose Escalation of BG-T0050EXPERIMENTALSequential cohorts of increasing dose levels of BG-T0050 will be evaluated as monotherapy.
Part 1b Dose Expansion of BG-T0050EXPERIMENTALThe recommended dose(s) for expansion (RDFE) for BG-T0050 from Part 1a will be evaluated.

Interventions

NameTypeDescription
BG-T0050DRUGAdministered subcutaneously
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Confirmed diagnosis of any of the below according to World Health Organization (WHO) classification 1. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) 2. Diffuse large B-cell lymphoma / high-grade B-cell lymphoma (DLBCL/HG-BCL) with MYC and BCL2 rearran...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 19, 2026NCT07881211NEW_TRIAL: changed
LOWOct 19, 2026NCT07881211NEW_TRIAL: changed
LOWOct 19, 2026NCT07881211NEW_TRIAL: changed

Explore more on BiopharmaWatch

BeOne Medicines Ltd. (ONC)Pipeline, catalysts, financials, insiders and newsDiffuse Large B-Cell Lymphoma disease mapEvery company developing for Diffuse Large B-Cell Lymphoma, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track